As the exclusivity period surrounding Entresto (Sacubitril Valsartan Sodium, LCZ696) continues to narrow, pharmaceutical companies worldwide are actively evaluating suppliers capable of delivering consistent, registration-grade Sacubitril Valsartan intermediates and API. This shift is not incidental — it reflects a well-documented patent timeline: the U.S. core patent for Entresto expired in July 2023, while the China compound patent is set to expire in 2026. This narrowing window has created what industry observers describe as a "golden window" for generic entry, prompting dozens of generic drug companies to search for qualified, reliable, and cost-competitive Sacubitril Calcium suppliers to support R&D, regulatory filing, and pre-launch inventory planning.
Why Direct Manufacturer Sourcing Matters for Sacubitril Valsartan
For companies preparing generic or follow-on submissions, the choice of supplier directly affects timelines, cost structure, and filing readiness. Shandong Tianming Pharmaceutical Group, headquartered in Jinan, Shandong Province, positions itself within this space as an R&D-driven pharmaceutical raw material and intermediate enterprise operating an integrated R&D-production model. The company traces its origins to Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010, with the group structure formally established in 2020.
A recurring pain point in this sourcing category is the need to coordinate multiple vendors across different stages of the synthesis route — starting materials, advanced intermediates, and final API — each introducing its own quality variability and lead-time risk. Shandong Tianming Pharmaceutical Group addresses this through a full-chain product matrix for the Sacubitril Valsartan Sodium series, offering a complete product ladder from starting materials through advanced intermediates to the final Sacubitril Valsartan Sodium API, which is the 1:1 molar ratio co-crystal of Sacubitril and Valsartan.
Full-Chain Intermediate Coverage
The Sacubitril Valsartan and Intermediates Series includes several documented components along the synthesis pathway:
- Sacubitril Valsartan Sodium (CAS 936623904) — the final drug substance, supplied for generic formulation development and commercial production.
- Sacubitril Calcium (CAS 1369773396) — an advanced intermediate used for Sacubitril Valsartan Sodium co-crystal preparation, which can also support independent intellectual property NCE development such as Sacubitril Alisartan Calcium.
- Starting material (CAS 1426129501), a chiral biphenyl-based tert-butyl carbamate ester used as the chiral starting material for Sacubitril synthesis.
- Ethoxycarbonylmethylene triphenylphosphorane (CAS 5717373), the Wittig reagent used for the olefination step.
- Unsaturated intermediate (CAS 1012341488), generated from the Wittig coupling reaction.
- Saturated chiral intermediate (CAS 1012341502), produced after hydrogenation.
- Deprotected chiral amine intermediate (CAS 149690120).
By maintaining this full ladder of intermediates under one roof, the company states that customers avoid the coordination costs typically associated with sourcing each synthesis stage from a different supplier — a factor that matters particularly for companies racing to establish supply chains ahead of the 2026 patent expiry in China.
Quality Specifications Relevant to Registration
Quality consistency is a frequent concern for companies evaluating Sacubitril Calcium and related intermediates, since even minor variability in chiral purity or impurity levels can affect regulatory filings. According to the company’s disclosed technical metrics, Sacubitril Calcium is produced with an individual impurity level below 0.1% and chiral purity above 99.5%. The company also states that it applies strict monitoring across the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form — all attributes that are commonly scrutinized during DMF and CEP filings.
This registration-grade quality control is supported by a documented annual R&D investment above 10% of revenue, compared with an industry average the company describes as around 5%. The group also operates under a GMP-compliant quality assurance system and holds ISO9001 Quality Management System Certification (Shandong Sihuan Pharmaceutical Co., Ltd., 2025; Guangxi Tianming Pharmaceutical Co., Ltd., 2024).
Production Scale and Delivery Capability
Scale is another practical consideration for generic companies planning pre-launch inventory. Shandong Tianming Pharmaceutical Group operates three coordinated production bases — Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Jining Tianming Pharmaceutical Co., Ltd. in Jining, and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi — with over 160 reactor vessels in total and an annual production capacity described as being in the hundreds of tons. The company reports gram-level to ton-level supply capability, covering laboratory small-batch trials, pilot scale-up, and commercial production stages within a single supply relationship.
For in-stock orders, delivery is stated at 7–15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability, though the company notes that expedited production scheduling is available for urgent projects.
Documentation Supporting Regulatory Filings
Beyond the physical product, generic manufacturers preparing filings require complete technical documentation. The company states it provides a Certificate of Analysis (COA), MOA methodology, impurity profile studies, and stability data intended to support DMF and CEP global regulatory filings. Full batch traceability — covering raw material receipt, reaction parameters, purification processes, and testing data — is maintained through the company’s CRM, ERP, and BPM digital management systems, which also support order management, inventory, and production scheduling.
Service Model for Technical Support
Sourcing decisions in this category often hinge on responsiveness during technical evaluation. Shandong Tianming Pharmaceutical Group describes a service model built on a 1-on-1 account manager paired with a technical engineer. Routine technical questions are addressed with reference solutions within 2 hours, while more complex technical issues are resolved with a written report within 24 hours. Periodic follow-up visits and on-site technical support are available for bulk and framework cooperation customers.
A Practical Consideration for Companies Evaluating Suppliers
For pharmaceutical companies and CDMO institutions assessing Sacubitril Valsartan sourcing options ahead of the 2026 China patent expiry, the relevant evaluation criteria typically include full-chain intermediate availability, documented impurity and chiral purity specifications, production capacity, delivery reliability, and completeness of regulatory documentation. Shandong Tianming Pharmaceutical Group, operating as a National High-Tech Enterprise with more than 400 employees and reporting over 2,000 cooperative customers across domestic and international markets, presents its Sacubitril Valsartan Sodium and Intermediates Series as one option within this evaluation process, built around the full-chain product matrix, registration-grade quality control, and scale delivery capabilities described above.
Tianming Pharmaceutical Group